VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Immune escape is a prerequisite for tumor development. To avoid the immune system, tumors develop different mechanisms, including T cell exhaustion, which is characterized by expression of immune inhibitory receptors, such as PD-1, CTLA-4, Tim-3, and a progressive loss of function. The recent development of therapies targeting PD-1 and CTLA-4 have raised great interest since they induced long-lasting objective responses in patients suffering from advanced metastatic tumors. However, the regulation of PD-1 expression, and thereby of exhaustion, is unclear. VEGF-A, a proangiogenic molecule produced by the tumors, plays a key role in the development of an immunosuppressive microenvironment. We report in the present work that VEGF-A produced in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved in CD8+ T cell exhaustion, which could be reverted by anti-angiogenic agents targeting VEGF-A–VEGFR. In view of these results, association of anti-angiogenic molecules with immunomodulators of inhibitory checkpoints may be of particular interest in VEGF-A-producing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have demonstrated that VEGF blockade can reverse T cell failure and enhance the therapeutic effect of ICI [59,60].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [59]
In the citing paper
“expression of co-inhibitory receptors, including PD-1 by CD8 + CTLs”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Voron et al., 2015
In the citing paper
“First, increased VEGF directly inhibits CTL trafficking, proliferation, and effector function22”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [22]
In the citing paper
“Secondly, VEGF could inhibit the maturation of DC, induce the exhaustion of T cells, promote the proliferation of Tregs, and increase the ratio of MDSCs [90–93].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“2015 Vol. 212 No. 2 139–148 www.jem.org/cgi/doi/10.1084/jem.20140559 139 Brief Definit ive Report One of the major processes involved in tumor appearance and growth is the capacity of tumor cells to develop escape mechanisms to the immune system (Schreiber et al., 2011).”
BackgroundInfluentialWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“The mechanisms involved in PD-1 expression and exhaustion of tumor-infiltrating T cells are poorly understood, even though a link to antigen persistence has been suggested (Wherry, 2011).”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · cited 1×
“In tumors or during chronic viral infections, PD-1 expression is maintained (Wherry et al., 2007).”
BackgroundTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 6×
“Cell surface-staining was performed on tumor-infiltrating cells using antiCD8 (53–6.7; eBioscience), anti–PD-1 (J43; eBioscience), anti–CTLA-4 (UC10-4B9; BioLegend), anti–Lag-3 (C9B7W; BioLegend), anti–Tim-3 (RMT3-23; BioLegend), anti–mouse VEGF-R2 (89B3A5; BioLegend), and anti–mouse VEGF-R1 (141522; R&D Systems).”
BackgroundInfluentialBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · cited 1×
“To determine whether VEGF-R1 or VEGF-R2 are involved in the T cells express these receptors the more they are dysfunctional (Blackburn et al., 2009).”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Cited by
Items 401–500 of 1,000
Hubbard, J. M., Tőke, E. R., Moretto, R., Graham, R. P., Youssoufian, H., Lőrincz, O., Molnár, L., Csiszovszki, Z., Mitchell, J. L., Wessling, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0112 · Cited by 38
Song, C. W., Kim, H., Cho, H., Kim, M., Paek, S.-H., Park, H. J., Griffin, R. J., Terezakis, S. A., & Cho, L. C. (2022) · Cancers · doi:10.3390/cancers14133273 · Cited by 38
“expression of PD-1 in CD8+ T-cells [79].”
BackgroundAndreuzzi, E., Fejza, A., Polano, M., Poletto, E., Camicia, L., Carobolante, G., Tarticchio, G., Todaro, F., Carlo, E. D., Scarpa, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02271-y · Cited by 40
Tumor Vasculature as an Emerging Pharmacological Target to Promote Anti-Tumor Immunity
Tzeng, H., & Huang, Y.-J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054422 · Cited by 38
“Sunitinib (VEGFR, TKI) VEGFR1, R2, and R3 colorectal cancer • Exhaustion of CD8T ↓ • Suppression of tumor growth by combining VEGF-A–VEGFR and PD-1 blockade [114]”
BackgroundThe role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers
Shen, L., Chai, Y., Zheng, X., & Xu, X. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08931-2 · Cited by 37
“This process also significantly inhibits the cytotoxicity of effector T cells [ 75, 76].”
BackgroundLamb, L. S., Sim, H., & McCormack, A. I. (2020) · Cancers · doi:10.3390/cancers12020308 · Cited by 37
“VEGF contributes to the pro-tumor immunosuppressive microenvironment by inhibiting dendritic cell maturation, accumulating myeloid-derived suppressor cells, and inducing T regulatory cells (T reg), as well as increasing the expression of inhibitory receptors on cytotoxic CD8+ T cells, including programmed cell death p…”
BackgroundMennitto, A., Huber, V., Ratta, R., Sepe, P., de Braud, F., Procopio, G., Guadalupi, V., Claps, M., Stellato, M., Daveri, E., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040930 · Cited by 37
“Furthermore, VEGF-A induces the upregulation of multiple immune checkpoints, such as PD-1, CTLA4, TIM3 and LAG3, in tumor-infiltrating CD8+ T cells, and VEGF-silencing potentiates tumor control mediated by the PD-1 blockade [63].”
BackgroundInteraction between Immunotherapy and Antiangiogenic Therapy for Cancer
Furukawa, K., Nagano, T., TACHIHARA, M. Y., Yamamoto, M., & Nishimura, Y. (2020) · Molecules · doi:10.3390/molecules25173900 · Cited by 40
Nakata, E., Fujiwara, T., Kunisada, T., Ito, T., Takihira, S., & Ozaki, T. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab005 · Cited by 36
Yuan, M., Zhu, Z., Mao, W., Wang, H., Qian, H., Wu, J., Guo, X., & Xu, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683502 · Cited by 33
“pre-clinical study, which suggested that the application of antiVEGF-A antibody (sunitinib) in CT26 tumor-bearing mice increased the infiltration of cytotoxic tumor-infiltrating lymphocytes (TIL) and decreased expression of PD-1 in CD8+T cells (36).”
BackgroundWang, X., Zhou, T., Chen, X., Wang, Y., Ding, Y., Tu, H., Gao, S., Wang, H., Tang, X., & Yang, Y. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004414 · Cited by 38
Anti-PD-1 combined with targeted therapy: Theory and practice in gastric and colorectal cancer
Chen, Y., Bai, B., Ying, K., Pan, H., & Xie, B. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188775 · Cited by 42
Mycotoxins and cellular senescence: the impact of oxidative stress, hypoxia, and immunosuppression
Li, Y., Nepovimová, E., Valko, M., Wu, Q., & Kuča, K. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03423-x · Cited by 39
Ouyang, P., Zhang, J., He, X., Yang, C., Zeng, D., & Xu, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1661545 · Cited by 54
Amin, A., & Hammers, H. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03120 · Cited by 38
How to schedule VEGF and PD-1 inhibitors in combination cancer therapy?
Lai, X., & Friedman, A. (2019) · BMC Systems Biology · doi:10.1186/s12918-019-0706-y · Cited by 37
“VEGF increases the PD-1 on T8 cells by a factor εGG [27].”
BackgroundResultInfluentialUncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives
Chacon, M. R., Pflüger, Y., Angel, M. O., Waisberg, F., & Enrico, D. H. (2020) · Cancers · doi:10.3390/cancers12092362 · Cited by 36
Chi, A., He, X., Hou, L., Nguyen, N. P., Zhu, G., Cameron, R. B., & Lee, J. M. (2021) · Cancers · doi:10.3390/cancers13122924 · Cited by 37
Emerging immunotherapies for bladder cancer
Kim, J. W., Tomita, Y., Trepel, J. B., & Apolo, A. B. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000177 · Cited by 36
“com reported that VEGF-A enhances expression of immune checkpoint receptors (including PD-1) on CD8þ T cells in murine tumors [83], suggesting that combining antiangiogenic agents targeting VEGF-”
BackgroundAngiogenesis in Dermatology – Insights of Molecular Mechanisms and Latest Developments
Richarz, N. A., Boada, A., & Carrascosa, J. M. (2017) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2016.12.001 · Cited by 38
“VEGF-A has shown to induce PD-1 (programmed death receptor 1) expression on the surface of tumor infiltrating CD8 cells and thus ameliorate immune response by increased induction of apoptotic signaling pathways on binding PD-L1 (programmed death receptor ligand 1) of melanoma cells.(50) Furthermore VEGF-A increases th…”
BackgroundCurrent Knowledge about the Peritumoral Microenvironment in Glioblastoma
Trevisi, G., & Mangiola, A. (2023) · Cancers · doi:10.3390/cancers15225460 · Cited by 41
“Indeed, expression of PD-1, a T-cell surface protein serving as an immune checkpoint which downregulates the immune system to prevent auto-immunity [88,89], is upregulated by VEGF-A [90].”
BackgroundOura, K., Morishita, A., Tadokoro, T., Fujita, K., Tani, J., & Kobara, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413590 · Cited by 41
“Furthermore, anti-VEGF therapy may promote CTL infiltration and activity in other types of cancer [112], and it may also be an important mechanism for influencing the immune cycle in HCC through VEGF inhibition.”
Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
Stolk, D. A., van der Vliet, H. J., de Gruijl, T. D., van Kooyk, Y., & Exley, M. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01990 · Cited by 34
Zhou, X., Hou, W., Gao, L., Shui, L., Cheng, Y., & Zhu, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01321 · Cited by 32
“A preclinical study in mice reported that tumor-associated VEGF enhanced expression of PD-1 and other inhibitory checkpoints involved in CD8 T cell exhaustion, such as CTLA4, TIM-3, and LAG-3, and targeting VEGF reverted expression of inhibitory checkpoints (51).”
BackgroundLessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
Mohr, R. U., Jost‐Brinkmann, F., Özdirik, B., Lambrecht, J., Hammerich, L., Loosen, S. H., Luedde, T., Demir, M., Tacke, F., & Roderburg, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652172 · Cited by 41
Liberini, V., Mariniello, A., Righi, L., Capozza, M., Delcuratolo, M. D., Terreno, E., Farsad, M., Volante, M., Novello, S., & Deandreis, D. (2021) · Cancers · doi:10.3390/cancers13184543 · Cited by 36
Evolving Treatment Approaches to Mucosal Melanoma
Zhang, S., Zhang, J., Guo, J., Si, L., & Bai, X. L. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01225-z · Cited by 34
Daly, R. J., Scott, A. M., Klein, O., & Ernst, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01656-z · Cited by 40
“Consistent with this observation, combination treatment of a high VEGFexpressing mouse model of colon cancer with antibodies against VEGF and PD-1 was significantly more effective than either monotherapy [87].”
BackgroundResultGremese, E., Alivernini, S., Ferraccioli, E. S., & Ferraccioli, G. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108395 · Cited by 39
Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney
Li, J., Li, X., & Li, C. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.09.005 · Cited by 33
Shitara, K., Janjigian, Y. Y., Ajani, J. A., Moehler, M. H., Yao, J. G., Wang, X., Chhibber, A., Pandya, D., Shen, L., Garrido, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03575-0 · Cited by 47
Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1
Hoeres, T., Wilhelm, M., Smetak, M., Holzmann, E., Schulze-Tanzil, G. G., & Birkmann, J. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13090 · Cited by 31
Boydell, E., Marinari, E., Migliorini, D., Dietrich, P., Patrikidou, A., & Dutoit, V. (2019) · Cancers · doi:10.3390/cancers11040464 · Cited by 32
Therapeutic Perspectives in the Systemic Treatment of Kaposi’s Sarcoma
Valantin, M., Royston, L., Hentzien, M., Jary, A., Makinson, A., Veyri, M., Brégigeon, S., Isnard, S., Palich, R., & Routy, J. (2022) · Cancers · doi:10.3390/cancers14030484 · Cited by 32
“Angiogenesis is now considered a driver of immunosuppression and immune evasion in the tumor microenvironment [77], with vascular endothelial growth factor (VEGF), a key mediator of angiogenesis, reported to upregulate immune checkpoints leading to T cell exhaustion [78,79].”
BackgroundXiao, M., Shi, Y., Jiang, S., Cao, M., Chen, W., Xu, Y. F., Xu, Z., & Wang, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1039378 · Cited by 37
“For example, high-level VEGF promotes CTL depletion by upregulating the expression of immune checkpoint molecules (PD-1/PD-L1, CTLA4, LAG3, TIM3) (52).”
BackgroundTargeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer
Kersh, A. E., Ng, S., Chang, Y. M., Sasaki, M., Thomas, S. N., Kissick, H. T., Lesinski, G. B., Kudchadkar, R. R., Waller, E. K., & Pollack, B. P. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1028 · Cited by 34
Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy
Huang, Y., Fan, H., & Ti, H. (2024) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2024.100902 · Cited by 54
Vascular Endothelial Growth Factor (VEGF) Family and the Immune System: Activators or Inhibitors?
Failla, C. M., Carbone, M. L., Ramondino, C., Bruni, E., & Orecchia, A. (2024) · Biomedicines · doi:10.3390/biomedicines13010006 · Cited by 38
Strategy to targeting the immune resistance and novel therapy in colorectal cancer
Wang, G., Wang, J., Guan, R., Sun, Y., Shi, F., Zhang, J., Li, Z., Gao, J., & Fu, X. (2018) · Cancer Medicine · doi:10.1002/cam4.1386 · Cited by 35
Joerger, M., Güller, U., Bastian, S., Driessen, C., & von Moos, R. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.11.04 · Cited by 32
“Furthermore, VEGF-A produced in the TME of selected solid tumors enhanced the expression of PD-1 involved in CD8+ T cell exhaustion (18).”
BackgroundImmuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma
Park, R., Eshrat, F., Al‐Jumayli, M., Saeed, A., & Saeed, A. (2020) · Vaccines · doi:10.3390/vaccines8030447 · Cited by 36
PD-1 immunobiology in glomerulonephritis and renal cell carcinoma
Curran, C. S., & Kopp, J. B. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02257-6 · Cited by 33
“This growth factor, which is also abundantly produced by RCC tumor cells, activates the expression of three CD8 T cell checkpoint receptor genes, encoding lymphocyte activation gene-3 (LAG3), T-cell immunoglobulin mucin-domain containing-3 (TIM-3) and PD-1 [109].”
BackgroundLi, X., Shi, H. R., Zhang, W., Bai, C., He, M., Ta, N., Huang, H., Ning, Y., Chen, F., Qin, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.690115 · Cited by 37
Checkpoint inhibitors and anti-angiogenic agents: a winning combination
Brest, P., Mograbi, B., Pagès, G., Hofman, P. M., & Milano, G. A. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02437-1 · Cited by 33
“Treg cells can promote the development and progression of cancer by suppressing the immune response against cancer cells by favouring overexpression of checkpoints on T cells including PD-1, CTLA4, TIM3 and LAG3 [26].”
BackgroundHypoxic tumor microenvironment: Destroyer of natural killer cell function
Zhang, Y., Guo, F., & Wang, Y. (2024) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2024.02.04 · Cited by 36
Song, J., Zhu, J. W., Jiang, Y., Guo, Y., Liu, S., Qiao, Y., Du, Y., & Li, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189277 · Cited by 36
Liu, C., Xu, D., Bai, X., Liu, B., Li, J., & Huang, J. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00694-1 · Cited by 32
Cho, R., Sakurai, Y., Jones, H. S., Akita, H., Hisaka, A., & Hatakeyama, H. (2020) · Cancers · doi:10.3390/cancers12123630 · Cited by 31
“As previously reported, the enhanced anti-tumor effect of ICIs combined with anti-angiogenesis was observed in subcutaneous xenograft models [24,25,28].”
BackgroundWalsh, R. J., & Tan, D. S. P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194523 · Cited by 35
Danlos, F., Texier, M., Job, B., Mouraud, S., Cassard, L., Baldini, C., Varga, A., Yurchenko, A. A., Rabeau, A., Champiat, S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0886 · Cited by 33
The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies
Xu, M. M., Pu, Y., Zhang, Y., & Fu, Y. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.12.007 · Cited by 33
“in a previously underappreciated role, inhibit DCs maturation, and promote the expansion of MDSCs and expression of PD-1 or other inhibitory checkpoints involved in CD8+ T cell exhaustion [34, 35].”
BackgroundPembrolizumab for the treatment of colorectal cancer
Coupez, D., Hulo, P., Touchefeu, Y., Bossard, C., & Bennouna, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1718095 · Cited by 33
The current landscape of therapies for hepatocellular carcinoma
Coffman, K., Xie, C., Hrones, D. M., Ghabra, S., Greten, T. F., & Monge, C. (2023) · Carcinogenesis · doi:10.1093/carcin/bgad052 · Cited by 33
Godiyal, Y., Maheshwari, D., Taniguchi, H., Zinzuwadia, S. S., Díaz, Y. M., Tewari, D., & Bishayee, A. (2024) · Military Medical Research · doi:10.1186/s40779-024-00586-9 · Cited by 52
Yu, J., Kong, X., & Feng, Y. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.14 · Cited by 73
Atezolizumab for the treatment of breast cancer
Basile, D., Pelizzari, G., Vitale, M. G., Lisanti, C., Cinausero, M., Iacono, D., & Puglisi, F. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1469619 · Cited by 30
Moretto, R., Corallo, S., Belfiore, A., Rossini, D., Boccaccino, A., Lonardi, S., Centonze, G., Morano, F., Germani, M. M., Loupakis, F., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.04.045 · Cited by 31
Combined targeted therapy and immunotherapy for cancer treatment
Guo, C., Huang, X., Xu, J., Zhang, X., Shen, Y., Liang, T., & Bai, X.-L. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i26.7643 · Cited by 32
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
Rahma, O. E., Tyan, K., Giobbie‐Hurder, A., Brohl, A. S., Bedard, P. L., Renouf, D. J., Sharon, E., STREICHER, H. Z., Hathaway, E. S., Cunningham, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003569 · Cited by 31
Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
Wesolowski, J., Tankiewicz‐Kwedlo, A., & Pawlak, D. (2022) · Cancers · doi:10.3390/cancers14163860 · Cited by 34
“A recent study demonstrated that VEGF-A produced in the tumor microenvironment increased the expression of PD-1 and other inhibitory checkpoints involved in CD8+ T-cell exhaustion, which could be counteracted by antiangiogenic agents targeting VEGF-A-VEGFR [27].”
BackgroundIndini, A., Fiorilla, I., Ponzone, L., Calautti, E., & Audrito, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179985 · Cited by 33
“The vascular-endothelial growth factor (VEGF) acts as an immune-suppressive cytokine, increasing the expression of inhibitory molecules promoting T cell exhaustion, and creating a selective endothelial layer which reduces cytotoxic T cell trafficking and extravasation to the TME, favoring the infiltration of T regs [7…”
BackgroundLi, Y., Liang, X., Li, H., & Chen, X. (2022) · Cancer · doi:10.1002/cncr.34457 · Cited by 32
“Moreover, antiVEGF treatment can also enhance PD1 inhibition, which is related to a reduction in immunosuppression and the promotion of Tcell infiltration in tumors.(9,10) Recently, the IMbrave150 trial (Clini calTr ials.”
BackgroundPositron emission tomography imaging sheds new light on hypoxia and antitumor therapies
Fang, H., Wang, X., Lan, X., & Jiang, D. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230002 · Cited by 31
Shafqat, A., Omer, M. H., Ahmed, E. N., Mushtaq, A. H., Ijaz, E., Ahmed, Z., AlKattan, K. M., & Yaqinuddin, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1200941 · Cited by 36
Fingerprint of the oxido-reductase ERO1: A protein disulfide bond producer and supporter of cancer
Zito, E., Guarrera, L., & Janssen-Heininger, Y. M. W. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189027 · Cited by 33
“As ERO1 regulates VEGF in TNBC, its inhibition may impair VEGF, enhancing the trafficking of tumor-reactive T cells to cancer and favoring immune surveillance [56,60].”
BackgroundThomas, A. A., Fisher, J. L., Hampton, T. H., Christensen, B. C., Tsongalis, G. J., Rahme, G. J., Whipple, C. A., Steel, S. E., Davis, M. C., Gaur, A. B., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1941-3 · Cited by 30
Chen, J. A., Ma, W., Yuan, J. D., & Li, T. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_9 · Cited by 31
Tu, B., He, Y., Chen, B., Wang, Y., Gao, Y., Shi, M., Liu, T., Asrorov, A. M., & Huang, Y. (2020) · Biomaterials Science · doi:10.1039/d0bm01516d · Cited by 28
Liu, Z., Liu, L., Lu, T., Wang, L., Li, Z., Jiao, D., & Han, X. (2021) · Journal of Oncology · doi:10.1155/2021/6664386 · Cited by 34
Iozzo, M., Sgrignani, G., Comito, G., Chiarugi, P., & Giannoni, E. (2021) · Cells · doi:10.3390/cells10123396 · Cited by 32
Baldini, C., Danlos, F., Varga, A., Texier, M., Halse, H. M., Mouraud, S., Cassard, L., Champiat, S., Signolle, N., Vuagnat, P., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02423-0 · Cited by 31
Shi, C., Wang, Y., Xue, J., & Zhou, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940288 · Cited by 43
Yang, X., Sun, Y.-Y., Wang, H., Li, D., Xu, G., & Huang, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.914385 · Cited by 30
“ICIs may restore the immune-supportive tumor microenvironment (TME) through inhibiting immune checkpoints.”
BackgroundInfluentialA cancer treatment based on synergy between anti-angiogenic and immune cell therapies
Soto-Ortiz, L., & Finley, S. D. (2016) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2016.01.026 · Cited by 29
“CD8+ T cell function is also affected by VEGF (Voron et al., 2015).”
BackgroundGe, Y., Zhou, Q., Pan, F., & Wang, R. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s505539 · Cited by 30
“55 Transforming Growth Factor-β (TGF-β) induces cancer-associated fibroblasts (CAFs) and interferes with the expression of CXCR3 on T cells, inhibiting T cell infiltration and disrupting chemokine-induced migration.”
Liu, K. G., Gupta, S., & Goel, S. (2016) · Oncotarget · doi:10.18632/oncotarget.14388 · Cited by 28
“In addition, immunotherapy in combination with agents that enhance T cell trafficking and infiltration into the tumor bed, such as VEGF inhibitors, may also potentially provide additional clinical benefit not seen with either modality alone (Figure 1) [61-63].”
BackgroundKilling the “BAD”: Challenges for immunotherapy in pancreatic cancer
Li, T., Wang, W., Yu, X., & Liu, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188384 · Cited by 27
A vasculature-centric approach to developing novel treatment options for glioblastoma
Wirsching, H., Roth, P., & Weller, M. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1881062 · Cited by 28
Immunomodulation by Inflammation during Liver and Gastrointestinal Tumorigenesis and Aging
Nagai, N., Kudo, Y., Aki, D., Nakagawa, H., & Taniguchi, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052238 · Cited by 32
“VEGF also causes immune suppression by inhibiting the maturation of DCs from progenitors [32], attracting MDSCs in the bone marrow to the periphery [33,34], inhibiting cytotoxic CD8+ T cells by inducing the expression of TOX, and upregulating production of PD-1 and other inhibitory checkpoints molecules [35,36].”
BackgroundLabadie, B. W., Balar, A. V., & Luke, J. J. (2021) · Cancers · doi:10.3390/cancers13215415 · Cited by 37
Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma
Shen, W., Chen, Y., Pan, L., Sheldon, M., Sun, Y., Yao, F., & Ma, L. (2022) · Cancers · doi:10.3390/cancers14205013 · Cited by 32
Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy
Feng, H., Zhuo, Y., Zhang, X., Li, Y., Li, Y., Duan, X., Shi, J., Xu, C., Gao, Y., & Yu, Z. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s381764 · Cited by 32
“95,96 Accordingly, it has been proposed that the modification of stromal cells might potentially restore successful antitumor immunity.”
Kocikowski, M., Dziubek, K., & Parys, M. (2020) · Cancers · doi:10.3390/cancers12040804 · Cited by 27
“Additionally, the role of modifications in glycosylation patterns and other post-translational modifications (PTMs) of PD-1 and PD-L1 proteins is relatively unexplored.”
BackgroundInfluentialOncogenic potential of SARS-CoV-2—targeting hallmarks of cancer pathways
Jaiswal, A., Shrivastav, S., Kushwaha, H. R., Chaturvedi, R., & Singh, R. P. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01818-0 · Cited by 37
Chemotherapy for advanced gastric cancer: future perspective in Japan
Shitara, K. (2016) · Gastric Cancer · doi:10.1007/s10120-016-0648-7 · Cited by 26
“VEGF-A in tumor tissues is reported to induce the expression of inhibitorymolecules and to exhaust CD8? T cells in a mouse model, indicating the possibility of the combined use of immune checkpoint inhibitors and a VEGF inhibitor [57].”
BackgroundPrognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma
Morimoto, Y., Tamura, R., Ohara, K., Kosugi, K., Oishi, Y., Kuranari, Y., Yoshida, K., & Toda, M. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03221-z · Cited by 27
Neoangiogenesis in Melanoma: An Issue in Biology and Systemic Treatment
Quaresmini, D., & Guida, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584903 · Cited by 30
“Relevantly for immunotherapy, VEGF pathway activation also enhances T cell exhaustion mediated by immune checkpoints like PDL1, CTLA4, TIM3, and LAG3 (25).”
BackgroundAddressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 31
Emerging Novel Combined CAR-T Cell Therapies
Nguyen, T. A., Johanning, G. L., & Shi, Y. H. (2022) · Cancers · doi:10.3390/cancers14061403 · Cited by 27
“Moreover, VEGF-A can induce the expression of PD-1 on tumor-infiltrating CD8-positive T cells, suggesting that CAR-T cells might benefit from VEGF-VEGFR pathway blockade [59].”
BackgroundYang, R., Pei, T., Huang, R., Xiao, Y., Yan, J., Zhu, J., Zheng, C., Xiao, W., & Huang, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.774440 · Cited by 32
Immune checkpoint inhibitors in ovarian cancer: where do we go from here?
Yoon, W.-H., DeFazio, A., & Kasherman, L. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.13 · Cited by 32
Han, R., Guo, H., Shi, J., Zhao, S., Jia, Y., Liu, X., Liu, Y., Cheng, L., Zhao, C., Li, X., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03389-w · Cited by 35
Advances in Systemic Therapy for Metastatic or Advanced Gastric Cancer
Shitara, K., & Ohtsu, A. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0138 · Cited by 25
Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges
Alfayez, M., & Borthakur, G. M. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1459184 · Cited by 27
“In solid tumors, VEGF was reported to inhibit antigen presentation by dendritic cells, upregulate PD-1, and enhance the expansion of Tregs [128,129].”
BackgroundInfluentialChen, J., Huang, N., Wei, W., Hu, J., Cao, Y.-M., Shen, Q., Lu, Z., Wang, Y., Wang, Y., & Ji, Q. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14031-z · Cited by 29
Feng, Y., Dai, Y., Gong, Z., Cheng, J., Zhang, L., Sun, C., Zeng, X., Jia, Q., & Zhu, B. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s162729 · Cited by 25
“…impaired infiltration of cytotoxic T cells (CTLs) in the TME may be related to the increased level of vascular endothelial growth factor A (VEGFA), 4 which facilitates vascularization without well-regulated expression of adhesion molecules, such as inter-cellular adhesion molecule-1 (ICAM-1) and…”
Chaudhary, R., Slebos, R. J. C., Song, F., McCleary‐Sharpe, K. P., Masannat, J., Tan, A. C., Wang, X., Amaladas, N., Wu, W., Hall, G. E., et al. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23275 · Cited by 28
“VEGF‐A enhances expression of PD‐1 and other inhibitory checkpoints involved in CD8 T cell exhaustion.(37) Unfortunately, we also observed evidence of immune surveillance evasion over time resulting in acquired resistance to prexasertib.”
BackgroundThe Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials
Özer, M., George, A., Goksu, S. Y., George, T. J., & Şahin, İ. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.801379 · Cited by 26
“Additionally, VEGF inhibits T-cell development and causes the upregulation of PD-1 and CTLA-4 expression on immune cells (36, 37).”
BackgroundCui, Y., Zhang, P., Liang, X., Xu, J., Liu, X., Wu, Y., Zhang, J., Wang, W. T., Zhang, F., & Guo, R. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3991639 · Cited by 31
Sun, L., Xu, X., Meng, F., Liu, Q., Wang, H., Li, X., Li, G., & Chen, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.980214 · Cited by 26
“VEGF was also reported to modulate the checkpoint expression of CD8+T cells in HCC (72).”
Background
Metadata
- Authors
- Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., Stockmann, C., Combe, P., Berger, A., Zinzindohoue, F., Yagita, H., Tartour, E., Taieb, J., & Terme, M.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Service d’immunologie biologique 2 , 3 , 4 , 5
- Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan 6
- INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, 75015 Paris, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-01-19
- Volume
- 212
- Issue
- 2
- Pages
- 139-148
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4322048
- OpenAlex
- W2156906256
- Cited by
- 1,179
- References
- 32
- Citations by year
- 2026: 81 · 2025: 100 · 2024: 121 · 2023: 142 · 2022: 169 · 2021: 147 · 2020: 127 · 2019: 92 · 2018: 81 · 2017: 51 · 2016: 50 · 2015: 16
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Ligue Contre le Cancer
- Assistance publique-Hôpitaux de Paris
- Fonds d’Etudes et de Recherche du Corps Médical
- Japan Society for the Promotion of Science (26290059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- VEGF-A, PD-1, CTLA-4, TIM-3, CD8+ T cell exhaustion, tumor immune evasion, tumor microenvironment, anti-angiogenic therapy, VEGFR inhibition, immune checkpoint inhibitors, cancer immunotherapy
- MeSH terms
- Animals, Disease Models, Animal, Female, Neoplasms, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Gene Expression Profiling, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.